ARVN · Arvinas, Inc.
$8.97
-0.04 (-0.44%)
At close · Aug 14
Market Cap
$582.59M
Shares
65.39M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| John G. Houston | CEO | $6,534,127 |
| John Houston | Former President and Chief Executive Officer | $6,534,127 |
| Noah Berkowitz | M.D., Ph.D. Chief Medical Officer | $3,593,956 |
| Andrew Saik | Chief Financial Officer and Treasurer | $3,362,314 |
| Angela Cacace | Chief Scientific Officer | $3,300,914 |
| Ian Taylor | Former President of Research and Development | $903,389 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| John Houston | President and Chief Executive Officer | $12,746,981 |
| John G. Houston | CEO | $12,746,981 |
| Noah Berkowitz | M.D., Ph.D. Chief Medical Officer | $5,981,935 |
| Ian Taylor | President of Research and Development | $4,219,660 |
| Randy Teel | Former interim Chief Financial Officer | $3,776,333 |
| Andrew Saik | Chief Financial Officer and Treasurer | $3,465,996 |
| Angela Cacace | Chief Scientific Officer | $2,972,309 |
| Sean Cassidy | Former Chief Financial Officer and Treasurer | $105,908 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| John Houston | President and Chief Executive Officer | $7,627,032 |
| John G. Houston | CEO | $7,627,032 |
| Ronald Peck | — | $2,742,972 |
| Ian Taylor | President of Research and Development | $2,732,885 |
| Sean Cassidy | Former Chief Financial Officer and Treasurer | $2,723,246 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| John Houston | President and Chief Executive Officer | $9,545,846 |
| John G. Houston | CEO | $9,545,846 |
| Former Chief Medical | Officer | $3,530,676 |
| Ronald Peck | Chief Medical Officer | $3,530,676 |
| Ian Taylor | President of Research and Development | $3,521,043 |
| Sean Cassidy | Former Chief Financial Officer and Treasurer | $3,512,044 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| John Houston | President and Chief Executive Officer | $12,601,014 |
| John G. Houston | CEO | $12,601,014 |
| Ronald Peck | Chief Medical Officer | $4,284,396 |
| Former Chief Medical | Officer | $4,284,396 |
| Ian Taylor | Chief Scientific Officer | $4,259,266 |
| Sean Cassidy | Former Chief Financial Officer | $4,240,192 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| John Houston | President and Chief Executive Officer | $8,019,781 |
| John G. Houston | CEO | $8,019,781 |
| Ronal Peck | M.D., Chief Medical Officer | $2,918,263 |
| Ronald Peck | Chief Medical Officer | $2,918,263 |
| Ian Taylor | Chief Scientific Officer | $2,900,163 |
| Sean Cassidy | Chief Financial Officer | $2,859,463 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| John Houston | President and Chief Executive Officer | $5,497,039 |
| John G. Houston | CEO | $5,497,039 |
| Sean Cassidy | Chief Financial Officer | $2,030,122 |
| Ronal Peck | M.D., Chief Medical Officer | $1,917,546 |
| Ronald Peck | Chief Medical Officer | $1,917,546 |
| Ian Taylor | Chief Scientific Officer | $1,545,117 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| John G. Houston | CEO | $6,279,556 |
| John Houston | President and Chief Executive Officer | $6,279,556 |
| Sean Cassidy | Chief Financial Officer | $2,800,904 |
| Ian Taylor | Ph.D., Chief Scientific Officer | $1,985,384 |
| Ronal Peck | M.D., Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Randy Teel, Ph.D. | a member of the Board | Appointed | 2026-02-12 |
| Briggs Morrison, M.D. | chair of the Board | Appointed | 2026-02-12 |
| Randy Teel, Ph.D. | president, CEO, and principal executive officer | Appointed | 2026-02-12 |
| John Houston, Ph.D. | chairperson of the Company's board of directors | Resigned | 2026-02-12 |
| John Houston, Ph.D. | president, chief executive officer ("CEO") | Resigned | 2026-02-12 |
| Laurie Smaldone Alsup | Class I director | Appointed | 2025-06-30 |
| John Houston | Class I director | Appointed | 2025-06-30 |
| Linda Bain | Class I director | Appointed | 2025-06-30 |
| John Young | Board of Directors | Resigned | 2025-06-30 |
| Ian Taylor | President of Research and Development | Resigned | 2025-06-06 |
| Andrew Saik | chief financial officer, treasurer and principal financial officer | Appointed | 2024-06-24 |
| Angela Cacace, Ph.D. | Chief Scientific Officer | Appointed | 2024-06-17 |
| Ian Taylor, Ph.D. | President of Research and Development | Appointed | 2024-06-17 |
| Noah Berkowitz, M.D., Ph.D. | chief medical officer | Appointed | 2024-03-18 |
| Randy Teel | interim Chief Financial Officer, Treasurer and principal financial officer | Appointed | 2024-02-20 |
| Everett Cunningham | director | Appointed | 2022-12-16 |
| David Loomis | principal accounting officer | Appointed | 2022-12-16 |
| Bradley Margus | Board of Directors | Resigned | 2022-12-16 |
| John Young | director | Appointed | 2022-08-19 |
| Liam Ratcliffe | Board of Directors | Resigned | 2022-08-19 |
Key facts
CIK
1655759
CUSIP
04335A105
13F (30d)
193 filings
192 filers
Visit website
Investor relations